PMS2P2

Across TCGA pan-cancer cohorts, PMS2P2 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated PMS2P2 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher PMS2P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PMS2P2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LIHC show a favorable association.

MESO, COAD, and ACC are the cancer types where PMS2P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Quartile	III,IV	0.264	0.508	.001	63	view →
COAD	OS	Tertile	II,III,IV	0.713	0.847	.012	25	view →
ACC	DFS	Median	II,III,IV	0.510	0.847	.002	21	view →
KIRC	DFS	Quartile	IV	0.351	0.651	.014	20	view →
LUAD	DFS	Median	III,IV	0.696	0.570	.017	18	view →
LIHC	OS	Quartile	III,IV	0.850	0.513	.006	18	view →
UCEC	DFS	Tertile	All	0.889	0.770	<.001	16	view →
UCS	OS	Tertile	IV	0.844	0.283	.030	12	view →
BLCA	OS	Quartile	III,IV	0.680	0.528	.021	12	view →
SKCM	DFS	Median	III,IV	0.376	0.148	.008	10	view →
CESC	OS	Median	III,IV	0.788	0.534	.021	8	view →
LUSC	DFS	Median	IV	0.827	0.134	.024	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

PMS2P2–MESO (DFS)

Open the MESO breakdown →